@article{46c9ecf632124fed9b14102362460b6f,
title = "Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme",
abstract = "The ORAL Surveillance trial found that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional cardiovascular (CV) risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib versus tumour necrosis factor inhibitors (TNFi).1 A post hoc analysis indicated that the increased risk of MACE with tofacitinib versus TNFi was apparent primarily in patients with a history of atherosclerotic CV disease (ASCVD), that is, pre-existing coronary artery, cerebrovascular or peripheral artery disease.2",
keywords = "Antirheumatic Agents, Arthritis, Rheumatoid, Cardiovascular Diseases",
author = "Maxime Dougados and Christina Charles-Schoeman and Zolt{\'a}n Szekanecz and Giles, {Jon T.} and Ytterberg, {Steven R.} and Bhatt, {Deepak L.} and Koch, {Gary G.} and Ivana Vranic and Joseph Wu and Cunshan Wang and Kenneth Kwok and Sujatha Menon and Connell, {Carol A.} and Arne Yndestad and Rivas, {Jose L.} and Buch, {Maya H.}",
note = "Funding Information: This study was sponsored by Pfizer. Medical writing support, under the direction of the authors, was provided by Julia King, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded by Pfizer, New York, New York, USA, in accordance with Good Publication Practice (GPP 2022) guidelines (Ann Intern Med 2022;175:1298–304). Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2023",
doi = "10.1136/ard-2022-223406",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
}